Harrow (HROW) Projected to Post Earnings on Monday

Harrow (NASDAQ:HROW) is anticipated to issue its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Harrow to post earnings of ($0.23) per share and revenue of $70.35 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same quarter last year, the company posted ($0.38) earnings per share. On average, analysts expect Harrow to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Harrow Trading Down 0.7%

Shares of NASDAQ:HROW traded down $0.28 during trading on Monday, reaching $38.49. The stock had a trading volume of 43,478 shares, compared to its average volume of 735,752. Harrow has a fifty-two week low of $28.54 and a fifty-two week high of $54.85. The stock has a market cap of $1.43 billion, a P/E ratio of -93.87 and a beta of 0.26. The business has a fifty day moving average price of $39.81 and a 200-day moving average price of $40.36. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HROW shares. Cantor Fitzgerald decreased their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. BTIG Research restated a “buy” rating and set a $63.00 price objective on shares of Harrow in a report on Tuesday, July 21st. Wall Street Zen downgraded Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, B. Riley Financial restated a “buy” rating and set a $65.00 price target (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harrow presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.43.

Insider Transactions at Harrow

In other news, Director Adrienne L. Graves acquired 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director directly owned 1,000 shares of the company’s stock, valued at $31,070. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew R. Boll purchased 3,500 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were bought at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the transaction, the chief financial officer directly owned 814,679 shares in the company, valued at approximately $24,358,902.10. This trade represents a 0.43% increase in their position. The SEC filing for this purchase provides additional information. 12.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Harrow

Several hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company increased its holdings in shares of Harrow by 2.1% in the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after buying an additional 341 shares in the last quarter. Captrust Financial Advisors lifted its holdings in shares of Harrow by 0.5% during the 4th quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock valued at $3,428,000 after buying an additional 376 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Harrow by 1.7% in the 3rd quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after buying an additional 500 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Harrow in the 4th quarter valued at approximately $26,000. Finally, Cetera Investment Advisers increased its holdings in Harrow by 2.6% in the fourth quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock worth $1,140,000 after buying an additional 597 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.